530 East 74th StreetNew York, NY 10021
Overview of Dr. Tan
Dr. Carlyn Rose Tan is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, Fox Chase Cancer Center, Temple University Hospital - Jeanes Campus, and Memorial Sloan Kettering Monmouth. She received her medical degree from Albert Einstein College of Medicine of Yeshiva University and has been in practice 5 years. She is one of 97 doctors at Fox Chase Cancer Center and one of 30 doctors at Temple University Hospital - Jeanes Campus who specialize in Oncology. She has more than 20 publications and over 500 citings.
Education & Training
Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2017
Cedars-Sinai Medical CenterResidency, Internal Medicine, 2011 - 2014
Albert Einstein College of MedicineClass of 2011
Certifications & Licensure
FL State Medical License 2021 - Present
CA State Medical License 2012 - 2026
PA State Medical License 2014 - 2026
NJ State Medical License 2020 - 2025
NY State Medical License 2019 - 2025
NC State Medical License 2020 - 2022
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis Start of enrollment: 2023 Mar 07
Roles: Contact, Principal Investigator
- A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Start of enrollment: 2022 Oct 27
Roles: Principal Investigator
Publications & Presentations
PubMed
- Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review.Benjamin Derman, Carlyn Tan, Ian Steinfield, Florence R Wilson, Dee Lin
Cancers. 2025-04-05 - Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up Dosing.Carlyn R Tan, Alice X Wang, David Nemirovsky, Andriy Derkach, Tala Shekarkhand
Blood Advances. 2025-03-06 - 1 citationsPhase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Up...Eric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, Kinga Hosszu, Sean M Devlin
Journal of Clinical Oncology. 2025-02-10
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
